MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 532047 | Name: KW-3635

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KW-3635 is a thromboxane A2 receptor antagonist.

Chemical Structure

KW-3635
KW-3635
CAS#N/A

Theoretical Analysis

MedKoo Cat#: 532047

Name: KW-3635

CAS#: N/A

Chemical Formula: C26H21N2O3-

Exact Mass: 409.1558

Molecular Weight: 409.47

Elemental Analysis: C, 76.27; H, 5.17; N, 6.84; O, 11.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KW-3635; KW 3635; KW635.
IUPAC/Chemical Name
(11E)-11-[2-(5,6-dimethylbenzimidazol-1-yl)ethylidene]-6H-benzo[c][1]benzoxepine-2-carboxylate
InChi Key
WZXFXUCKNJCHJG-ZVBGSRNCSA-M
InChi Code
InChI=1S/C26H22N2O3/c1-16-11-23-24(12-17(16)2)28(15-27-23)10-9-21-20-6-4-3-5-19(20)14-31-25-8-7-18(26(29)30)13-22(21)25/h3-9,11-13,15H,10,14H2,1-2H3,(H,29,30)/p-1/b21-9+
SMILES Code
O=C(C1=CC=C(OCC2=CC=CC=C2/C3=C\CN4C5=CC(C)=C(C)C=C5N=C4)C3=C1)[O-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 409.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Higo K, Karasawa A. The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery. Biol Pharm Bull. 1994 Jul;17(7):902-6. PubMed PMID: 8000373. 2: Shirakura S, Higo K, Takeda M, Karasawa A. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol. 1994 Jun;65(2):93-8. PubMed PMID: 7967232. 3: Kawakage M, Sato K, Karasawa A. Protective effect of KW-3635, a specific thromboxane A2-receptor antagonist, on experimental glomerulonephritis in mice. Jpn J Pharmacol. 1994 Jun;65(2):163-6. PubMed PMID: 7967228. 4: Satoh H, Kobayashi T, Higo K, Karasawa A. Protective effects of KW-3635, a thromboxane A2 antagonist, on arachidonic acid-induced transient cerebral ischemia in dogs. Jpn J Pharmacol. 1994 May;65(1):45-50. PubMed PMID: 8089929. 5: Higo K, Karasawa A. Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs. Jpn J Pharmacol. 1993 Dec;63(4):521-3. PubMed PMID: 8121085. 6: Kawakage M, Mizumoto H, Nukui E, Sato S, Karasawa A. Effects of KW-3635, a specific thromboxane A2-receptor antagonist, on the development of lupus nephritis in NZB x NZW F1 mice. Jpn J Pharmacol. 1993 Dec;63(4):433-8. PubMed PMID: 8121078. 7: Higo K, Sano J, Karasawa A, Kubo K. The novel thromboxane A2 receptor antagonist KW-3635 reduces infarct size in a canine model of coronary occlusion and reperfusion. Arch Int Pharmacodyn Ther. 1993 May-Jun;323:32-49. PubMed PMID: 8250642. 8: Kawakage M, Ishihara N, Karasawa A, Kase H. [Effects of KW-3635 on the diuretic action of furosemide in rats]. Nihon Yakurigaku Zasshi. 1993 Jan;101(1):33-8. Japanese. PubMed PMID: 8444379. 9: Miki I, Kishibayashi N, Nonaka H, Ohshima E, Takami H, Obase H, Ishii A. Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64. PubMed PMID: 1434130. 10: Miki I, Ishii A. Characterization of thromboxane A2/prostaglandin H2 receptors in porcine coronary artery--the inhibitory effect of a novel dibenzoxepin derivative, KW-3635. Thromb Haemost. 1992 May 4;67(5):582-4. PubMed PMID: 1387741. 11: Karasawa A, Taylor PA 3rd, Lefer AM. Protective effects of KW-3635, a novel thromboxane A2 antagonist, in murine traumatic shock. Eur J Pharmacol. 1990 Jun 21;182(1):1-8. PubMed PMID: 2401310.